MovDisordV3, Main, Exploration, bibRecordById, pubmed:16440332

Botulinum toxin type A for drooling in Parkinson's disease: A double‐blind, randomized, placebo‐controlled study

Identifieur interne : 003555 ( Main/Exploration ); précédent : 003554; suivant : 003556

Botulinum toxin type A for drooling in Parkinson's disease: A double‐blind, randomized, placebo‐controlled study

Auteurs : Giovanni Lagalla [Italie] ; Marzia Millevolte [Italie] ; Marianna Capecci [Italie] ; Leandro Provinciali [Italie] ; Maria Gabriella Ceravolo [Italie]

Source :

Movement Disorders [ 0885-3185 ] ; 2006-05.

RBID : ISTEX:008D9F1EA04DF6C91C76881F4854A812F88ACC8C

Descripteurs français

Pascal (Inist)
- Bontoxilysin, Etude double insu, Parkinson maladie, Placebo, Sialorrhée, Système nerveux pathologie.

English descriptors

KwdEn :
- Aged, Bontoxilysin, Botox, Botulinum Toxins, Type A (therapeutic use), Double blind study, Double-Blind Method, Female, Humans, Male, Middle Aged, Nervous system diseases, Neuromuscular Agents (therapeutic use), Parkinson Disease (complications), Parkinson Disease (drug therapy), Parkinson Disease (physiopathology), Parkinson disease, Parkinson's disease, Placebo, Sialorrhea, Sialorrhea (drug therapy), Sialorrhea (etiology), botulinum toxin type A, drooling.
MESH :
- chemical , therapeutic use : Botulinum Toxins, Type A, Neuromuscular Agents.
- complications : Parkinson Disease.
- drug therapy : Parkinson Disease, Sialorrhea.
- etiology : Sialorrhea.
- physiopathology : Parkinson Disease.
- Aged, Double-Blind Method, Female, Humans, Male, Middle Aged.

Abstract

To investigate the safety and efficacy of botulinum toxin type A (BoNTX) treatment to reduce sialorrhea in Parkinson's disease (PD), a double‐blind, randomized, placebo‐controlled study enrolled 32 PD patients complaining of excessive drooling. Patients received either 50 U Botox in each parotid gland or placebo without using ultrasound guidance. Subjects treated with BoNTX experienced a reduction in both drooling frequency and familial and social disability (Time × Group effect: P < 0.01), as well as in saliva production (Time × Group effect: P < 0.0001). No adverse events were recorded. BoNTX injections are safe and effective treatment for the management of PD‐related drooling. © 2006 Movement Disorder Society

Url:

https://api.istex.fr/document/008D9F1EA04DF6C91C76881F4854A812F88ACC8C/fulltext/pdf

DOI: 10.1002/mds.20793

Affiliations:

Italie

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Botulinum toxin type A for drooling in Parkinson's disease: A double‐blind, randomized, placebo‐controlled study</title>
<author><name sortKey="Lagalla, Giovanni" sort="Lagalla, Giovanni" uniqKey="Lagalla G" first="Giovanni" last="Lagalla">Giovanni Lagalla</name>
</author>
<author><name sortKey="Millevolte, Marzia" sort="Millevolte, Marzia" uniqKey="Millevolte M" first="Marzia" last="Millevolte">Marzia Millevolte</name>
</author>
<author><name sortKey="Capecci, Marianna" sort="Capecci, Marianna" uniqKey="Capecci M" first="Marianna" last="Capecci">Marianna Capecci</name>
</author>
<author><name sortKey="Provinciali, Leandro" sort="Provinciali, Leandro" uniqKey="Provinciali L" first="Leandro" last="Provinciali">Leandro Provinciali</name>
</author>
<author><name sortKey="Ceravolo, Maria Gabriella" sort="Ceravolo, Maria Gabriella" uniqKey="Ceravolo M" first="Maria Gabriella" last="Ceravolo">Maria Gabriella Ceravolo</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:008D9F1EA04DF6C91C76881F4854A812F88ACC8C</idno>
<date when="2006" year="2006">2006</date>
<idno type="doi">10.1002/mds.20793</idno>
<idno type="url">https://api.istex.fr/document/008D9F1EA04DF6C91C76881F4854A812F88ACC8C/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002F62</idno>
<idno type="wicri:Area/Istex/Curation">002F62</idno>
<idno type="wicri:Area/Istex/Checkpoint">002016</idno>
<idno type="wicri:doubleKey">0885-3185:2006:Lagalla G:botulinum:toxin:type</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:16440332</idno>
<idno type="wicri:Area/PubMed/Corpus">002D75</idno>
<idno type="wicri:Area/PubMed/Curation">002D75</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002E44</idno>
<idno type="wicri:Area/Ncbi/Merge">001554</idno>
<idno type="wicri:Area/Ncbi/Curation">001554</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001554</idno>
<idno type="wicri:doubleKey">0885-3185:2006:Lagalla G:botulinum:toxin:type</idno>
<idno type="wicri:Area/Main/Merge">004870</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:06-0289041</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001B43</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001178</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001C04</idno>
<idno type="wicri:doubleKey">0885-3185:2006:Lagalla G:botulinum:toxin:type</idno>
<idno type="wicri:Area/Main/Merge">004C99</idno>
<idno type="wicri:Area/Main/Curation">003555</idno>
<idno type="wicri:Area/Main/Exploration">003555</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Botulinum toxin type A for drooling in Parkinson's disease: A double‐blind, randomized, placebo‐controlled study</title>
<author><name sortKey="Lagalla, Giovanni" sort="Lagalla, Giovanni" uniqKey="Lagalla G" first="Giovanni" last="Lagalla">Giovanni Lagalla</name>
<affiliation wicri:level="1"><country xml:lang="fr">Italie</country>
<wicri:regionArea>Clinica di Neuroriabilitazione, Dipartimento di Neuroscienze, Università Politecnica delle Marche, Az. Ospedaliero Universitaria Ospedali Riuniti, Ancona</wicri:regionArea>
<wicri:noRegion>Ancona</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Millevolte, Marzia" sort="Millevolte, Marzia" uniqKey="Millevolte M" first="Marzia" last="Millevolte">Marzia Millevolte</name>
<affiliation wicri:level="1"><country xml:lang="fr">Italie</country>
<wicri:regionArea>Clinica di Neuroriabilitazione, Dipartimento di Neuroscienze, Università Politecnica delle Marche, Az. Ospedaliero Universitaria Ospedali Riuniti, Ancona</wicri:regionArea>
<wicri:noRegion>Ancona</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Capecci, Marianna" sort="Capecci, Marianna" uniqKey="Capecci M" first="Marianna" last="Capecci">Marianna Capecci</name>
<affiliation wicri:level="1"><country xml:lang="fr">Italie</country>
<wicri:regionArea>Clinica di Neuroriabilitazione, Dipartimento di Neuroscienze, Università Politecnica delle Marche, Az. Ospedaliero Universitaria Ospedali Riuniti, Ancona</wicri:regionArea>
<wicri:noRegion>Ancona</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Provinciali, Leandro" sort="Provinciali, Leandro" uniqKey="Provinciali L" first="Leandro" last="Provinciali">Leandro Provinciali</name>
<affiliation wicri:level="1"><country xml:lang="fr">Italie</country>
<wicri:regionArea>Clinica Neurologica, Dipartimento di Neuroscienze, Università Politecnica delle Marche, Az. Ospedaliero Universitaria Ospedali Riuniti, Ancona</wicri:regionArea>
<wicri:noRegion>Ancona</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ceravolo, Maria Gabriella" sort="Ceravolo, Maria Gabriella" uniqKey="Ceravolo M" first="Maria Gabriella" last="Ceravolo">Maria Gabriella Ceravolo</name>
<affiliation wicri:level="1"><country xml:lang="fr">Italie</country>
<wicri:regionArea>Clinica di Neuroriabilitazione, Dipartimento di Neuroscienze, Università Politecnica delle Marche, Az. Ospedaliero Universitaria Ospedali Riuniti, Ancona</wicri:regionArea>
<wicri:noRegion>Ancona</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2006-05">2006-05</date>
<biblScope unit="vol">21</biblScope>
<biblScope unit="issue">5</biblScope>
<biblScope unit="page" from="704">704</biblScope>
<biblScope unit="page" to="707">707</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">008D9F1EA04DF6C91C76881F4854A812F88ACC8C</idno>
<idno type="DOI">10.1002/mds.20793</idno>
<idno type="ArticleID">MDS20793</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Bontoxilysin</term>
<term>Botox</term>
<term>Botulinum Toxins, Type A (therapeutic use)</term>
<term>Double blind study</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Nervous system diseases</term>
<term>Neuromuscular Agents (therapeutic use)</term>
<term>Parkinson Disease (complications)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (physiopathology)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Placebo</term>
<term>Sialorrhea</term>
<term>Sialorrhea (drug therapy)</term>
<term>Sialorrhea (etiology)</term>
<term>botulinum toxin type A</term>
<term>drooling</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Botulinum Toxins, Type A</term>
<term>Neuromuscular Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
<term>Sialorrhea</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Sialorrhea</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Bontoxilysin</term>
<term>Etude double insu</term>
<term>Parkinson maladie</term>
<term>Placebo</term>
<term>Sialorrhée</term>
<term>Système nerveux pathologie</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">To investigate the safety and efficacy of botulinum toxin type A (BoNTX) treatment to reduce sialorrhea in Parkinson's disease (PD), a double‐blind, randomized, placebo‐controlled study enrolled 32 PD patients complaining of excessive drooling. Patients received either 50 U Botox in each parotid gland or placebo without using ultrasound guidance. Subjects treated with BoNTX experienced a reduction in both drooling frequency and familial and social disability (Time × Group effect: P < 0.01), as well as in saliva production (Time × Group effect: P < 0.0001). No adverse events were recorded. BoNTX injections are safe and effective treatment for the management of PD‐related drooling. © 2006 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>Italie</li>
</country>
</list>
<tree><country name="Italie"><noRegion><name sortKey="Lagalla, Giovanni" sort="Lagalla, Giovanni" uniqKey="Lagalla G" first="Giovanni" last="Lagalla">Giovanni Lagalla</name>
</noRegion>
<name sortKey="Capecci, Marianna" sort="Capecci, Marianna" uniqKey="Capecci M" first="Marianna" last="Capecci">Marianna Capecci</name>
<name sortKey="Ceravolo, Maria Gabriella" sort="Ceravolo, Maria Gabriella" uniqKey="Ceravolo M" first="Maria Gabriella" last="Ceravolo">Maria Gabriella Ceravolo</name>
<name sortKey="Millevolte, Marzia" sort="Millevolte, Marzia" uniqKey="Millevolte M" first="Marzia" last="Millevolte">Marzia Millevolte</name>
<name sortKey="Provinciali, Leandro" sort="Provinciali, Leandro" uniqKey="Provinciali L" first="Leandro" last="Provinciali">Leandro Provinciali</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003555 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003555 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:008D9F1EA04DF6C91C76881F4854A812F88ACC8C
   |texte=   Botulinum toxin type A for drooling in Parkinson's disease: A double‐blind, randomized, placebo‐controlled study
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Botulinum toxin type A for drooling in Parkinson's disease: A double‐blind, randomized, placebo‐controlled study

Botulinum toxin type A for drooling in Parkinson's disease: A double‐blind, randomized, placebo‐controlled study

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.